RESUMO
Objectives: To explore the feasibility and safety of EEN with Freka Trelumina and Supportan after esophageal and cardiac carcinoma operation.Methods: 30 patients with esophageal and cardiac carcinoma were retained Freka Trelumina in to jejunum during the operation.All patients were given EEN with Supportan on the 3rd day after the operation.The complication and resumption of digestive tract functions were observed and recorded carefully.Renal and Liver functions were examined on the 8~(th) day after operation.Results: No mortality and serious complication occurred in all patients during the period of study.There was no evidence of damage of EEN to the renal and liver function. Conclusion: EEN with Freka Trelumina and Supportan after esophageal and cardiac carcinoma is feasible and safe.